Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2024
0mins
Source: Businesswire
Financial Highlights: Anebulo Pharmaceuticals reported a net loss of $2.2 million for the first quarter of fiscal 2025, with operating expenses slightly decreasing compared to the previous year. The company has cash reserves of $1.4 million and access to an additional $10 million through a loan agreement.
Development Updates: Anebulo received a $1.9 million grant from the National Institute on Drug Abuse to support the development of its intravenous formulation of selonabant, aimed at treating acute cannabis-induced toxicity, particularly in children, with clinical studies expected to begin in 2025.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
